Maze Therapeutics (NASDAQ:MAZE) CEO Jason Coloma Sells 6,982 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 6,982 shares of Maze Therapeutics stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $26.00, for a total value of $181,532.00. Following the transaction, the chief executive officer directly owned 28,523 shares in the company, valued at approximately $741,598. This trade represents a 19.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Stock Performance

MAZE traded down $0.30 during trading on Wednesday, hitting $26.05. 401,776 shares of the stock were exchanged, compared to its average volume of 709,447. The firm has a market capitalization of $1.44 billion, a P/E ratio of -10.30 and a beta of 2.50. Maze Therapeutics, Inc. has a 1-year low of $9.73 and a 1-year high of $53.65. The stock has a fifty day moving average price of $30.19 and a two-hundred day moving average price of $37.63. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The business had revenue of $20.00 million during the quarter. As a group, sell-side analysts predict that Maze Therapeutics, Inc. will post -2.74 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of MAZE. Royal Bank of Canada increased its holdings in shares of Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares during the period. GF Fund Management CO. LTD. acquired a new position in Maze Therapeutics during the fourth quarter worth $39,000. Ameritas Investment Partners Inc. grew its holdings in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after acquiring an additional 738 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Maze Therapeutics during the fourth quarter worth $43,000. Finally, Russell Investments Group Ltd. grew its holdings in Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after acquiring an additional 1,725 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Wedbush lifted their price target on Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research report on Monday, March 16th. HC Wainwright boosted their target price on Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. BTIG Research reissued a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday, March 25th. Truist Financial dropped their target price on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, April 14th. Finally, Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.